Cardiac Issues in Childhood Cancer Survivors After Adriamycin Treatment
Author Information
Author(s): F. Pein, O. Sakiroglu, M. Dahan, J. Lebidois, P. Merlet, A. Shamsaldin, E. Villain, F. de Vathaire, D. Sidi, O. Hartmann
Primary Institution: Institut Gustave Roussy
Hypothesis
The study aims to evaluate the long-term risk of cardiac disease after adriamycin therapy for childhood cancer and the influence of other drugs and radiotherapy on this risk.
Conclusion
The study found a significant increase in cardiac failure and abnormalities in childhood cancer survivors treated with adriamycin, particularly with higher doses and radiation exposure.
Supporting Evidence
- Patients who received higher doses of adriamycin had a greater risk of cardiac failure.
- The risk of cardiac failure increased with time since the first adriamycin treatment.
- Radiation dose to the heart was a significant risk factor for cardiac disease.
- Female patients showed a higher sensitivity to radiation therapy.
- Adriamycin therapy was associated with long-term cardiac toxicity.
Takeaway
Kids who had cancer and got a certain medicine called adriamycin might have heart problems later in life, especially if they got a lot of it or had radiation treatment.
Methodology
The study involved a retrospective analysis of 447 childhood cancer survivors who received adriamycin, with cardiac evaluations conducted through various diagnostic methods including echocardiography and Holter ECG.
Potential Biases
The non-inclusion of a substantial number of patients, who were older and more frequently male, may introduce selection bias.
Limitations
The study had a significant dropout rate, with 49% of initially targeted patients not included, which may affect the generalizability of the results.
Participant Demographics
The study included 229 childhood cancer survivors, with a male to female ratio of approximately 1.65:1.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI: 9–29%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website